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Transcatheter Aortic Valve Implantation
in Patients With Mitral Prosthesis
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tTo the Editor: Transcatheter aortic valve implantation (TAVI) is an
important therapeutic strategy for high-risk patients with severe
aortic stenosis. Recently, this technique has proven to be as
effective as surgery in reducing mortality at 2 years in this
population (1). Historically, the presence of a mitral prosthesis has
represented a special concern in the context of a TAVI procedure.
Indeed, the rigid prosthetic mitral struts may reduce stability and
increase the risk of prosthesis embolization during or after deploy-
ment (2). Furthermore, close interaction between the mitral
prosthetic valve struts has the potential to prevent correct device
expansion and, over time, valve durability. We report a multicenter
experience of TAVI in patients with a mitral prosthesis.
Between February 2008 and March 2012, 40 (n  40) patients
ffected by severe symptomatic aortic stenosis and with a mitral
rosthesis underwent TAVI using both the self-expanding
edtronic CoreValve (CV; Minneapolis, Minnesota) and the
alloon-expandable Edwards SAPIEN (ES) heart valve (Edwards
ifesciences, Irvine, California) at 9 Italian centers with a high
olume of TAVIs. For each patient, contraindication to conventional
urgical aortic valve replacement was established based on a consensus
f a local multidisciplinary heart team before consideration for TAVI.
esign features of the CV and ES prostheses and technical details of
he procedures have been described previously (3). Multislice com-
uted tomography was performed in all patients to assess carefully
elationship between the aortic annulus and the mitral prosthetic ring
nd strut extending into the left ventricular outflow tract.
All procedures were performed under local anesthesia or general
nesthesia and endotracheal intubation, under fluoroscopic guid-
nce and transesophageal echocardiography, according to individ-
al institutional practice. All outcomes were defined according to
he Valve Academic Research Consortium (14).
The mean patient age was 76.3  9.5 years (range: 30 to 88
years), and female gender was more represented (n  29, 72.5%).
he Logistic EuroScore I and Society of Thoracic Surgery scores
ere 26.3  17.5% (range: 6.2% to 72.5%) and 13.4  11.5%
range: 3.3% to 46.7%), respectively. Thirty patients (75%) had
mechanical and 10 patients (15%) had a biological mitral
rosthesis. The mean interval between TAVI and the most recent
peration was 15.1  5.5 years (range: 8 to 26 years). The vast
ajority of patients were in permanent atrial fibrillation (n  31,
7.5%) and were receiving oral anticoagulant therapy (n  34,
5%). One patient had a degenerated aortic bioprosthesis. In 1
atient (2.5%) with severe left ventricular impairment, partial
etachment of a 31-mm Carpentier-Edwards Perimount biopros-
hesis (Edwards Lifesciences, Irvine, California) already was pres-
nt at the moment of the TAVI screening phase. No other cases of
itral prosthesis dysfunction were documented before TAVI.
hirty patients (75%) had 2 or more tricuspid regurgitation
mean systolic pulmonary arterial pressure (sPSP): 49.3  15.2
mm Hg), and 18 (45%) had a moderate to severe right ventricle
dysfunction investigated by tricuspid annular systolic velocity aevaluation and tricuspid annular plane systolic excursion measure-
ment.
A CV prosthesis was implanted in 28 cases (70%) using a
transfemoral (n  23, 57.5%), trans-subclavian (n  3, 7.5%), or
transaortic (n  2, 5%) approach; otherwise, the ES valve was
mplanted in 12 cases (30%) using both transfemoral (n  6, 15%)
nd transapical (n  6, 15%) routes. In the immediate term, Valve
cademic Research Consortium–defined device success was
chieved in 97.5% of cases. In the patient previously mentioned
ith pre-existing mitral bioprosthesis dysfunction, device success
as not obtained because of moderate or severe perivalvular leak
fter 29-mm CV implantation, which was maintained even after
ggressive post-dilation. In 5 patients (12.5%), balloon shift during
re-dilation was documented, and in 3 patients (7.5%), (3
arpentier-Edwards Perimount Bioprosthetic Valve recipients),
rosthesis (ES device) shift during deployment also was noted;
onetheless, a satisfactory implant was accomplished. No evidence
f prosthesis shift was noted in cases not documenting balloon
hift during valvuloplasty. Evaluation of balloon and prosthesis
ehavior during the procedure was not achievable in 8 cases
12.5%). Overall, dilation after the procedure was performed
neventfully in 5 patients (12.5%), in 4 after CV implantation and
n 1 after ES implantation. No deformation of the nitinol tubing
f the CV device or the cobalt-chromium and steel stent of the ES
evice, nor distortion or malfunction of the mechanical valve in
itral position, occurred in any patients.
No cases of procedural death, stroke, myocardial infarction, or
rgent cardiac surgery occurred. One case of transient ischemic
ttack after 29-mm CV implantation was reported. All patients
ere discharged after a mean hospitalization of 14 days on dual
ntiplatelet therapy for 3 months. All patients with a mechanical
itral prosthesis remained under oral anticoagulant therapy (target
nternational normalized ratio: 3).
At a median follow-up of 560 days (range: 35 to 1,488 days),
patients died at 14 days (heart failure), 32 days (multiorgan
ailure), 168 days (heart failure), 776 days (heart failure), and
,040 days (acute renal failure) after the procedure, thus
mparting all-cause and cardiovascular mortality rates of 12.5%
nd 7.5%, respectively. Disabling bleeding, major bleeding, and
trokes complicated 7.5% (n  3), 20% (n  8), and 2.5% (n 
) of procedures, respectively; all of these complications oc-
urred during hospitalization. In 5 patients (12.5%), 1 or more
ehospitalization for cardiac reasons was needed. Reoperation was
eported in 2 cases: a 60-year-old woman with severely impaired left
entricular function underwent cardiac transplantation and concom-
tant CV prosthesis removal, and a 30-year-old man with pre-existing
itral prosthesis dysfunction and residual moderate or severe perival-
ular leak after TAVI underwent combined surgical aortic and mitral
eplacement with mechanical prostheses 2 months after TAVI, after
he clinical and hemodynamic conditions improved, to allow a surgical
pproach.
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October 30, 2012:1839–43At follow-up, New York Heart Association functional class III or
IV was present in 10% of the population. Mean transaortic gradients
decreased from 44.3  17.2 mm Hg (before TAVI) to 10.2 
5.2 mm Hg (after TAVI), and aortic valve area increased from 0.6
0.2 cm2 (before TAVI) to 1.9 0.3 cm2 (after TAVI; p 0.001 for
oth comparisons). Perivalvular leak of 2 or more was present in
5% of patients. No cases of intraprosthetic regurgitation were
eported. Left ventricular ejection fraction also improved slightly from
6.6  13.5% (before TAVI) to 50.5  11.9% (after TAVI, p 
.045). Finally, a minimum significant reduction in mean systolic
ulmonary arterial pressure was reported (from 49.5  15.6 mm Hg
o 43.4  10.2 mm Hg, p  0.032).
In summary, this multicenter study demonstrated that TAVI with
oth available devices can be performed safely and effectively in
atients with a pre-existing biological and mechanical mitral prosthe-
is. Further larger series and longer follow-up are warranted to
etermine better the safety, efficacy, and durability of TAVI in this
articular population.
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Level-Dependent Magnetic
Resonance Imaging in Patients
With Coronary Artery Disease
Arnold et al. (1) should be commended for their recent study in which
they evaluated the clinical usefulness of blood oxygen level-dependent
(BOLD) magnetic resonance imaging. They used 3-Tesla cardiac
magnetic resonance and steady-state free precession sequence to
overcome technical limitations encountered in the previous studies
and reported a high diagnostic accuracy of BOLD imaging to identify
anatomical and functional significance of coronary artery disease.
However, the following pertinent points require further clarification.
A significantly large percentage of acute coronary syndromesof admission, regardless of their diabetes status (2–4). Further,
undiagnosed impaired glucose tolerance is very common in pa-
tients with acute coronary syndromes at presentation, and the
preadmission status of glucose tolerance cannot be relied on solely
(2–4). Hence, it would be important to know if the authors made
an attempt to evaluate the diagnostic performance of BOLD
imaging in the setting of various blood glucose levels.
Because BOLD imaging exploits the differences in the magnetic
property of oxyhemoglobin and deoxyhemoglobin. It would be
interesting to know the effect of conditions like anemia, which
affect blood oxygenation, on the diagnostic performance of BOLD
imaging. The same also applies to other factors that affect the
oxygen dissociation curve.
In the present context, a high false positive rate, limited spatial
coverage, and uncertainties over the clinical implications of addi-
tional information obtained through BOLD imaging raise the
concern that its use would lead to an additional layering of a
diagnostic test without any proven clinical benefit.
